The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction.

Association of polymorphisms in platelet and hemostasis system genes with acute myocardial infarction. Am Heart J (2007) 1.05

PharmGKB summary: very important pharmacogene information for angiotensin-converting enzyme. Pharmacogenet Genomics (2010) 0.86

Pharmacogenetics of lipid diseases. Hum Genomics (2004) 0.85

ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet (2009) 0.84

The PlA1/A2 polymorphism of glycoprotein IIIa as a risk factor for myocardial infarction: a meta-analysis. PLoS One (2014) 0.84

Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Am Heart J (2007) 0.81

Effect of PlA1/A2 glycoprotein IIIa gene polymorphism on the long-term outcome after successful coronary stenting. Thromb J (2007) 0.79

Statins decrease mortality in Lebanese patients with sepsis: A multicenter study. Pharm Pract (Granada) (2013) 0.78

Pharmacogenetics of cardiovascular drug therapy. Clin Cases Miner Bone Metab (2009) 0.75

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76

A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med (1997) 19.93

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med (1992) 18.74

The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA (2000) 12.86

Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation (1990) 9.74

Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med (2001) 9.31

Factors influencing infarct size following experimental coronary artery occlusions. Circulation (1971) 7.04

Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med (1996) 6.92

A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med (1991) 6.13

The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation (1982) 5.56

The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50

TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation (2000) 5.15

Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr (1999) 5.12

Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 5.00

A prospective evaluation of an angiotensin-converting-enzyme gene polymorphism and the risk of ischemic heart disease. N Engl J Med (1995) 4.94

TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation (1996) 4.41

Myocardial infarct size and ventricular function in rats. Circ Res (1979) 4.33

Effects of beta-adrenergic blockade on the cardiac response to maximal and submaximal exercise in man. J Clin Invest (1965) 4.23

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol (2001) 4.20

Myocardial reperfusion: a double-edged sword? J Clin Invest (1985) 4.12

A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med (1980) 3.98

Control of heart rate by the autonomic nervous system. Studies in man on the interrelation between baroreceptor mechanisms and exercise. Circ Res (1966) 3.95

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1999) 3.90

Idiopathic hypertrophic subaortic stenosis. Clinical analysis of 126 patients with emphasis on the natural history. Circulation (1968) 3.82

A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. N Engl J Med (1993) 3.75

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA (1996) 3.69

Control of myocardial oxygen consumption: physiologic and clinical considerations. Am J Cardiol (1971) 3.68

Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation (2000) 3.66

Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA (2001) 3.59

Effects of diet and sodium intake on blood pressure: subgroup analysis of the DASH-sodium trial. Ann Intern Med (2001) 3.56

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol (2000) 3.54

Aortic stenosis. Circulation (1968) 3.49

Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet (2000) 3.39

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. Circulation (1999) 3.26

Defective cardiac parasympathetic control in patients with heart disease. N Engl J Med (1971) 3.24

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation (1998) 3.19

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet (2009) 3.13

Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med (1997) 3.13

Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr (2001) 3.12

Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis (1998) 3.09

Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 3.07

ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). Circulation (2000) 3.02

Mechanism of action of calcium-channel-blocking agents. N Engl J Med (1982) 2.99

Effect of captopril on progressive ventricular dilatation after anterior myocardial infarction. N Engl J Med (1988) 2.98

Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation (1998) 2.97

Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation (2000) 2.93

AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation (2001) 2.79

A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: an InTIME II substudy. Lancet (2001) 2.78

Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation (2005) 2.77

Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation (1994) 2.74

Increased pulse pressure and risk of heart failure in the elderly. JAMA (1999) 2.74

Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med (1992) 2.72

Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med (1991) 2.68

Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst (1994) 2.68

Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men. Am J Epidemiol (1992) 2.68

Clinical significance of mitral regurgitation after acute myocardial infarction. Survival and Ventricular Enlargement Investigators. Circulation (1997) 2.64

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation (1999) 2.59

Influence of the thyroid state on the intrinsic contractile properties and energy stores of the myocardium. J Clin Invest (1967) 2.51

Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. N Engl J Med (1996) 2.49

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation (2000) 2.47

Progressive ventricular remodeling in rat with myocardial infarction. Am J Physiol (1991) 2.40

Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. N Engl J Med (1990) 2.37

Unstable angina: an etiologic approach to management. Circulation (1998) 2.31

The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation (1965) 2.30

Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res (1999) 2.30

Oxygen consumption of the heart. Newer concepts of its multifactoral determination. Am J Cardiol (1968) 2.29

Coronary-artery surgery at the crossroads. N Engl J Med (1977) 2.28

Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest (1973) 2.28

Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II. Eur Heart J (2001) 2.28

Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet (1989) 2.28

The relation between dietary intake and adipose tissue composition of selected fatty acids in US women. Am J Clin Nutr (1998) 2.24

Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res (1985) 2.23

Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med (1998) 2.22